

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

## BioCardia Inc. (BCDA-NASDAQ) – Buy Rated;

August 31, 2022

### BioCardia announces DSMB Review – OK to Continue

Jason Kolbert

Managing Director & Senior Analyst  
jkolbert@dawsonjames.com

*BioCardia, Inc. announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP Cell Therapy Heart Failure Trial (clinicaltrials.gov Identifier: NCT02438306), for which FDA granted Breakthrough Designation earlier this year.*

#### Investment Highlights:

**BCDA-01:** The CardiAMP Heart Failure Trial (BCDA-01): The ongoing multi-center, double-blinded, randomized (3:2), controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. The trial's primary endpoint is an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. We anticipate complete enrollment later this year with the top-line data next year. Good data would be transformative for the company and the heart failure space.

**What did the DSMB say?** The DSMB based their review on available data for all participating patients enrolled, including 101 patients at or past the 12-month primary endpoint. The DSMB performed a risk-benefit assessment, indicated no significant safety concerns, and recommended that the study continue as designed. The DSMB also recommended that BioCardia consider implementing an adaptive statistical analysis plan which could enable an early readout for study treatment efficacy.


**2<sup>nd</sup> Quarter Results:** BioCardia spent \$2.5M in the quarter and closed the period with \$8.6M in cash. We do anticipate the company is likely to raise capital.

**Valuation:** Our product models run out to the year 2030. For CardiAMP and CardiALLO and all the related cardiac indications, each represents blockbuster markets. We adjusted our model for current and future dilution. Our risk cuts in our projected revenues are at 90% cut (or just a 10% probability of success), and for non-ischemic indications, just 1% probability of success, all but eliminating them from our future projections. In addition, in our free cash flow (FCFF), discounted EPS (EPS), and sum-of-the-parts (SOP) models, we apply a risk rate (r) of 30% on top of the revised risk cuts in our models. Our share count is projected for 2030 and assumes multiple raises. Our models are equal-weighted, averaged, and rounded to the nearest whole number to derive a fair value of \$3.0.

**Risks:** Partnership risks, Commercialization risks, financial risks, Clinical and Regulatory risks, and Legal and Intellectual Property risks.



Current Price			
Current Price	\$2.05		
Price Target			
Price Target	\$3.00		
Stock Data			
52-Week Range	\$1.10	-	\$3.96
Shares Outstanding (mil.)	17.8		
Market Capitalization (mil.)	\$36		
Enterprise Value (mil.)	\$36		
Debt to Capital	0%		
Book Value/Share	\$2.62		
Price/Book	0.8		
Average Three Months Trading Volume (K)	52		
Insider Ownership	24.7%		
Institutional Ownership	18.3%		
Short interest (mil.)	0.2%		
Dividend / Yield	\$0.00/0.0%		



**Exhibit 1. Product Pipeline**

Product Candidate (Pathway)	Preclinical	Phase 1	Phase 2	Phase 3	Catalysts	
<b>Autologous BCDA-01</b>	CardiAMP® for Ischemic Heart Failure (HF) uses Helix				Q1 DSMB Readout	} <b>Funded by Medicare</b>
<b>Autologous BCDA-02</b>	CardiAMP® for Chronic Myocardial Ischemia uses Helix				Safety Readout Roll in Cohort	
<b>NK1R+ Allogenic BCDA-03</b>	CardiALLO™ for Ischemic HF uses Helix				IND acceptance	
<b>NK1R+ Allogenic BCDA-04</b>	COVID-19 ARDS				IND Acceptance	} <b>Funded by partners</b>
<b>Helix Partner-CellProThera</b>	Acute Infarction					
<b>Helix Partner-RECARDIO</b>	Heart Failure					

Additional preclinical evaluations ongoing.

Source: BioCardia

**Exhibit 2. The Best of Both Worlds – Autologous and Allogenic Approaches to Heart Failure**

**CardiAMP cell therapy (BCDA-01, 02)**

- Regulated and manufactured as a procedure kit with anticipated low cost of goods and long shelf life
- For both leading indications, CardiAMP fits into standard interventional cardiology device channels
- Most components approved in EU and/or USA, but not for cardiovascular therapeutic usage



**CardiALLO cell therapy (BCDA-03)**

- Neurokinin 1 receptor positive for Substance P, the primary neuropeptide for pain
- Treats patients not possible to be treated with CardiAMP
- Potential orphan indication
- “Off the shelf” cell therapy
- Leverages delivery system



Source: BioCardia

**Product Modeling Assumptions**

1. We base our market share estimates for BioCardia's therapies on multiple assumptions around the product attributes associated with product delivery and outcomes. Given the blockbuster size of the U.S. and E.U. H.F. markets, the projected revenues become enormous quickly. However, the failure rate of therapeutics has also been high in the heart failure space. To balance these two factors, we apply between a 90% to 99% risk reduction (risk cut) to the net revenues in our models (U.S. & Europe) for the various indications and products.
2. We assume CardiAMP and CardiALLO will initially launch at \$50,000 per therapeutic course. Our projected market share grows over a six-year launch cycle, with CardiAMP at 20% of the total market in the year 2030, and CardiALLO achieves a 15% share of the total market by the year 2030.
3. Based on BioCardia's estimation of completing enrollment of the pivotal Phase 3 trial of BCDA-01 later this year and a standard FDA review time of 10 months suggests a launch in 2024/2025 is possible. We expect BCDA-02 to be a fast follower with approval and launch a year after BCDA-01, in 2026. We apply a 90% risk cut to our CardiAMP revenue model to adjust for the risk of approval.
4. We expect BCDA-03 (CardiALLO) to reach the market by 2027; however, we apply a therapeutic risk cut of 99% (or just a 1% probability of success) in our product model for conservatism.

**Exhibit 3. Market Models:**

	2022	2023	2024	2025	2026	2027	2028	2029	2030
<b>BCDA-01 Heart Failure</b>									
U.S. Prevalance CHF	5,015,015	5,020,030	5,025,050	5,030,075	5,035,105	5,040,140	5,045,180	5,050,226	5,055,276
Market Size Growth (Annual)	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Candidates (Class II & III) for Therapy	501,502	502,003	502,505	503,008	503,511	504,014	504,518	505,023	505,528
Market Share Penetration				3.0%	6.0%	7.0%	8.0%	10.0%	14.0%
Number of Patients Procedures	0	0	0	15,090	30,211	35,281	40,361	50,502	70,774
Cost of Therapy \$	20,120	20,160	20,201	20,241	20,282	20,322	20,363	20,404	20,444
Price Growth	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Probability of Success	1%	1%	1%	1%	1%	1%	1%	1%	1%
U.S. Annual Sales (M) \$	-	-	-	3	6	7	8	10	14
<b>BCDA-01 Heart Failure E.U.</b>									
U.S. Prevalance CHF	9,027,027	9,036,054	9,045,090	9,054,135	9,063,189	9,072,253	9,081,325	9,090,406	9,099,496
Market Size Growth (Annual)	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Candidates (Class II & III) for Therapy	902,703	903,605	904,509	905,414	906,319	907,225	908,132	909,041	909,950
Market Share Penetration					1.0%	3.0%	5.0%	10.0%	12.0%
Number of Patients Procedures	0	0	0	0	9,063	27,217	45,407	90,904	109,194
Cost of Therapy \$	30,180	30,241	30,301	30,362	30,423	30,483	30,544	30,605	30,667
Price Growth	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Probability of Success	1%	1%	1%	1%	1%	1%	1%	1%	1%
E.U. Annual Sales (M) \$	-	-	-	-	3	8	14	28	33
<b>BCDA-02 Heart Failure</b>									
U.S. Prevalance CHF	5,228,392	5,306,818	5,386,420	5,467,216	5,549,225	5,632,463	5,716,950	5,802,704	5,889,745
Market Size Growth (Annual)	1.5%	1.5%	1.5%	1.5%	1.5%	1.5%	1.5%	1.5%	1.5%
Candidates (Chronic Myocardial Ischemia) for Therapy	209,136	212,273	215,457	218,689	221,969	225,299	228,678	232,108	235,590
Market Share Penetration	0.0%	0.0%	2.0%	5.0%	10.0%	15.0%	20.0%	20.0%	20.0%
Number of Patients Procedures	0	0	4,309	10,934	22,197	33,795	45,736	46,422	47,118
Cost of Therapy \$	20,120	20,160	20,201	20,241	20,282	20,322	20,363	20,404	20,444
Price Growth	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Probability of Success	10%	10%	10%	10%	10%	10%	10%	10%	10%
U.S. Annual Sales (M) \$	-	-	9	22	45	69	93	95	96
<b>BCDA-02 Heart Failure E.U.</b>									
U.S. Prevalance CHF	9,217,733	9,291,474	9,365,806	9,440,733	9,516,259	9,592,389	9,669,128	9,746,481	9,824,453
Market Size Growth (Annual)	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%	0.8%
Candidates (Chronic Myocardial Ischemia) for Therapy	506,975	511,031	515,119	519,240	523,394	527,581	531,802	536,056	540,345
Market Share Penetration	0.0%	0.0%	0.0%	0.0%	2.0%	5.0%	10.0%	15.0%	16.0%
Number of Patients Procedures	0	0	0	0	10,468	26,379	53,180	80,408	86,455
Cost of Therapy \$	30,180	30,241	30,301	30,362	30,423	30,483	30,544	30,605	30,667
Price Growth	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Probability of Success	10%	10%	10%	10%	10%	10%	10%	10%	10%
U.S. Annual Sales (M) \$	-	-	-	-	32	80	162	246	265
<b>BCDA-03 Heart Failure</b>									
U.S. Prevalance CHF	5,015,015	5,020,030	5,025,050	5,030,075	5,035,105	5,040,140	5,045,180	5,050,226	5,055,276
Market Size Growth (Annual)	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Candidates (Class II & III) for Therapy	150,450	150,601	150,752	150,902	151,053	151,204	151,355	151,507	151,658
Market Share Penetration	0.0%	0.0%	0.0%	0.0%	0.0%	2.0%	5.0%	10.0%	15.0%
Number of Patients Procedures	0	0	0	0	0	3,024	7,568	15,151	22,749
Cost of Therapy \$	-	-	-	-	-	22,500	22,545	22,590	22,635
Price Growth	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Probability of Success	1%	1%	1%	1%	1%	1%	1%	1%	1%
U.S. Annual Sales (M) \$	-	-	-	-	-	1	2	3	5
<b>BCDA-03 Heart Failure E.U.</b>									
U.S. Prevalance CHF	9,027,027	9,036,054	9,045,090	9,054,135	9,063,189	9,072,253	9,081,325	9,090,406	9,099,496
Market Size Growth (Annual)	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Candidates (Class II & III) for Therapy	270,811	271,082	271,353	271,624	271,896	272,168	272,440	272,712	272,985
Market Share Penetration	0.0%	0.0%	0.0%	0.0%	0.0%	2.0%	5.0%	10.0%	15.0%
Number of Patients Procedures	0	0	0	0	0	5,443	13,622	27,271	40,948
Cost of Therapy \$	-	-	-	-	-	29,500	29,559	29,618	29,677
Price Growth	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Probability of Success	1%	1%	1%	1%	1%	1%	1%	1%	1%
U.S. Annual Sales (M) \$	-	-	-	-	-	2	4	8	12

Source: Dawson James Estimates

**Exhibit 4. Income Statement**


BioCardia Inc: Income Statement (\$000)																	
BCDA: YE December	2018A	2019A	2020A	2021A	1Q22A	2Q22A	3Q22E	4Q22E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Net product revenue	282	300	23	1													
Collaboration agreement revenue	343	382	122	1,014													
BCDA-01 CardiaAMP Cell Therapy revenues US		0	0	0	0	0	0	0	0	0	0	3,054	6,127	7,170	8,219	10,304	14,469
BCDA-01 CardiaAMP Cell Therapy revenues EU					0	0	0	0	0	0	0	0	2,757	8,297	13,869	27,822	33,486
BCDA-02 CardiaAMP Cell Therapy revenues US											8,705	22,133	45,019	68,679	93,131	94,717	96,330
BCDA-02 CardiaAMP Cell Therapy revenues EU													3,185	80,412	162,435	246,094	265,129
BCDA-03 CardALLO Cell Therapy revenues US														680	1,706	3,423	5,149
BCDA-03 CardALLO Cell Therapy revenues EU														1,606	4,027	8,077	12,152
<b>Total Product Sales</b>	<b>625</b>	<b>599</b>	<b>145</b>	<b>1,015</b>	<b>60</b>	<b>974</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>8,705</b>	<b>25,187</b>	<b>57,088</b>	<b>166,844</b>	<b>283,387</b>	<b>390,436</b>	<b>426,716</b>
<b>Product Sales &amp; Royalties &amp; Milestones</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>8,705</b>	<b>25,187</b>	<b>51,146</b>	<b>78,135</b>	<b>107,082</b>	<b>116,521</b>	<b>128,101</b>
<b>Expenses</b>																	
Cost of goods sold	517	543	4	24			0	0	0	0	2,176	6,045	13,130	36,706	59,511	78,087	85,343
			3%	2%	30%	30%	30%	30%			25%	24%	23%	22%	21%	20%	20%
Research and Development	8,453	8,876	9,809	8,558	2,186	2,304	2,500	2,500	6,367	7,004	7,354	7,722	8,108	8,513	8,939	9,386	9,855
Selling, general and administrative	5,757	6,045	5,861	5,087	1,201	1,166	2,000	2,000		22,000	23,100	24,255	25,468	26,741	28,078	29,482	30,956
<b>Total expenses</b>	<b>14,727</b>	<b>15,192</b>	<b>15,674</b>	<b>13,645</b>	<b>3,387</b>	<b>3,470</b>	<b>4,500</b>	<b>4,500</b>	<b>15,857</b>	<b>28,424</b>	<b>32,021</b>	<b>37,382</b>	<b>46,034</b>	<b>71,255</b>	<b>95,788</b>	<b>116,178</b>	<b>125,338</b>
Operating income (Loss)	(14,102)	(14,593)	(15,529)	(12,630)	(3,327)	(2,496)	(4,500)	(4,500)	(15,857)	(28,424)	(23,316)	(12,195)	11,054	95,589	187,599	274,259	301,378
Interest expense																	
Interest Income	118	23	21	9													
Other expense	(3)	(1)	504	(2)	2	(1)											
<b>Total other income</b>	<b>115</b>	<b>(1)</b>	<b>504</b>	<b>(2)</b>	<b>2</b>	<b>(1)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Pretax Income</b>	<b>(13,987)</b>	<b>(14,571)</b>	<b>(15,004)</b>	<b>(12,623)</b>	<b>(3,325)</b>	<b>(2,497)</b>	<b>(4,500)</b>	<b>(4,500)</b>	<b>(15,857)</b>	<b>(28,424)</b>	<b>(23,316)</b>	<b>(12,195)</b>	<b>11,054</b>	<b>95,589</b>	<b>187,599</b>	<b>274,259</b>	<b>301,378</b>
Income Tax Benefit (Provision)											(4,663)	(2,927)	2,653	22,941	52,528	82,278	102,468
<b>Tax Rate</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>0%</b>	<b>20%</b>	<b>24%</b>	<b>24%</b>	<b>24%</b>	<b>28%</b>	<b>30%</b>	<b>34%</b>
<b>GAAP Net Income (loss)</b>	<b>(13,987)</b>	<b>(14,571)</b>	<b>(15,004)</b>	<b>(12,623)</b>	<b>(3,325)</b>	<b>(2,497)</b>	<b>(4,500)</b>	<b>(4,500)</b>	<b>(15,857)</b>	<b>(28,424)</b>	<b>(18,653)</b>	<b>(9,268)</b>	<b>8,401</b>	<b>72,648</b>	<b>135,071</b>	<b>191,981</b>	<b>198,909</b>
Deemed Dividend on Preferred Stock																	
<b>GAAP-EPS</b>	<b>(0.37)</b>	<b>(0.92)</b>	<b>(1.48)</b>	<b>(0.75)</b>	<b>(0.19)</b>	<b>(0.14)</b>	<b>(0.25)</b>	<b>(0.25)</b>	<b>(0.91)</b>	<b>(1.60)</b>	<b>(1.05)</b>	<b>(0.52)</b>	<b>0.47</b>	<b>4.03</b>	<b>7.47</b>	<b>10.57</b>	<b>10.91</b>
GAAP EPS (dil)	(0.37)	(2.13)	(1.55)	(0.29)	(0.07)	(0.04)	(0.08)	(0.08)	(0.29)	(0.50)	(0.33)	(0.16)	0.15	1.25	2.32	3.28	3.39
Weighted shares basic	38,285	15,761	10,118	16,917	17,066	17,651	17,669	17,686	17,518	17,731	17,802	17,873	17,945	18,016	18,089	18,161	18,234
Weighted shares dil	38,285	15,136	13,445	44,209	46,823	56,870	56,927	56,984	54,401	57,127	57,356	57,585	57,816	58,048	58,280	58,514	58,748

Source: Dawson James estimates, company reports

Companies mentioned in this report:

**Important Disclosures:**

**Price Chart:**



**Price target and ratings changes over the past three years:**

- Initiated – Buy – September 17, 2019 – Price Target \$24.00
- Update – Buy – November 20, 2019 – Price Target \$24.00
- Update – Buy – February 18, 2020 – Price Target \$24.00
- Update – Buy – May 5, 2020 – Price Target \$24.00
- Update – Buy – July 7, 2020 – Price Target \$24.00
- Update – Buy – August 13, 2020 – Price Target \$24.00
- Update – Buy – October 9, 2020 – Price Target \$24.00
- Price Target Change – Buy – November 11, 2020 – Price Target \$14.00
- Price Target Change – Buy – March 2, 2021 – Price Target \$5.00
- Rating Change – Buy to Neutral – April 15, 2021 – Price Target NA
- Update - Neutral – June 24, 2021 – Price Target NA
- Update - Neutral – December 14, 2021 – Price Target NA
- Rating Change – Buy – January 24, 2022 – Price Target \$4.0
- Update – Buy – February 3, 2022 – Price Target \$4.0
- Update – Buy – February 14, 2022 – Price Target \$4.0
- Update – Buy – March 3, 2022 – Price Target \$4.0
- Update – Buy – March 30, 2022 – Price Target \$4.0
- Update Price Target Change – Buy – April 19, 2022 – Price Target \$3.0
- Update – Buy – May 18, 2022 – Price Target \$3.0
- Update – Buy – August 31, 2022 – Price Target \$3.0

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of August 1, 2022, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or

employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 29-Aug-22

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	28	90%	5	18%
Market Perform (Neutral)	2	6%	0	0%
Market Underperform (Sell)	1	3%	0	0%
Total	31	100%	5	16%

**Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.